We build solutions that leverage routinely generated clinical data to help clinicians find patients with undiagnosed or undertreated cardiovascular disease.
Tempus Next is an AI-platform that enables healthcare systems to add an “intelligent layer” onto routinely generated data to help find appropriate patients for proactive care and disease management. Tempus Next ingests multimodal data, runs AI-based algorithms, and surfaces insights for care teams to evaluate and action.
60+
algorithms to identify potential care gaps across 18 cardiovascular diseases
1.5M+
patients screened
70+
hospitals nationwide are currently powered by Tempus Next
40K+
patients screened per month
Identify and minimize care gaps with Tempus Next.1 With our AI-platform, you’ll experience:
Seamlessly and securely integrates into your hospital’s EHR system to monitor cardiac patients for optimal treatment
Analyzes free text from clinical notes and other data sources using Advanced NLP
Provides team support to ensure you exceed your objectives for superior care
Encompasses a broad cardiac service line, helping care teams enable comprehensive cardiac disease care
Tempus Next includes screening algorithms for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) using clinician reports from abdominal ultrasounds and CTs, in addition to all other available patient data. Our system follows patients through progression from low severity to high severity.
Within cardiomyopathies, our screening protocols address care across non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac amyloidosis, pulmonary hypertension, and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like LVAD or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists.
Our electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.2 Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.2 Tempus Next continuously monitors patient data to find at-risk patients, and alert the patient’s care team of any needed follow-up or disease progression.
Tempus Next also screens for an array of additional conditions including congestive heart failure, acute coronary syndrome, ischemic heart diseases, hypertension, and dyslipidemia. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.3
Tempus Next includes screening algorithms for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) using clinician reports from abdominal ultrasounds and CTs, in addition to all other available patient data. Our system follows patients through progression from low severity to high severity.
Our Structural Heart capabilities include screening for appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation.
Within cardiomyopathies, our screening protocols address care across non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac amyloidosis, pulmonary hypertension, and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like LVAD or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists.
Our electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.2 Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.2 Tempus Next continuously monitors patient data to find at-risk patients, and alert the patient’s care team of any needed follow-up or disease progression.
Tempus Next also screens for an array of additional conditions including congestive heart failure, acute coronary syndrome, ischemic heart diseases, hypertension, and dyslipidemia. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.3
Atrial fibrillation (AF) is associated with substantial morbidity, especially when it goes undetected. If new-onset AF can be predicted, targeted screening could possibly be used to find it early. In this study, we explore if a deep neural network can predict new-onset AF from the resting 12-lead ECG and study whether this prediction may help identify those at risk of AF-related stroke.
Read moreIn this study, we developed a novel ECG-based machine learning approach to predict multiple structural heart conditions, hypothesizing that a composite model would yield higher prevalence and positive predictive values to facilitate meaningful recommendations for echocardiography.
Read moreWe have launched a multi-site prospective study with our beta partners to test our algorithms for atrial fibrillation and structural heart disease. The study is called ‘ECG-AID’ and is expected to enroll 600-1,000 patients to validate prospective performance across multiple patient populations and data systems.
Read moreSocial Determinants of Health are increasingly being recognized as critical, independent prognosticators in cardiovascular disease. In this study, we explore if our ML model provides a holistic picture of mortality prediction to understand the role in care following TAVI.
Read moreThis study assessed transthoracic echocardiography (TTE), clinical and socioeconomic (SES) factors as predictors of progression from moderate to severe tricuspid regurgitation (TR) and showed that race/TTE indices offer insights into personalized management of patients with moderate TR.
Read moreThis study explores our platform that uses a rules-based algorithm to search EHRs for heart valve disease among patients treated by healthcare systems in the US to help provide a solution.
Read moreIn this Alan S. Pearlman Research Award Winning analysis, we uncover that significant TR is associated with considerable risk of clinical outcomes, and that a ML-based approach to identify phenogroups may aid in the timing and selection of therapy.
Read moreThis study assessed echocardiographic (Echo) and demographic predictors of moderate TR progression using Natural Language Processing (NLP) to further support that insights from NLP can help to improve the performance of disease prediction.
Read moreTempus announced the U.S. FDA has granted Breakthrough Device Designation for its ECG Analysis Platform. Developed in collaboration with Geisinger, it aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter.
Read more1 Husband G.; D”amico A.; Hasnie U.; Batra N.; Cochrun S.; Gann A.; Li E.; Nguyen D.; Philip George A.; Soto M.; Rogers C.; Ahmed M.; Andrikopoulou E.; UAB Hospital, Birmingham, United States of America; University of South Alabama, Mobile, United States of America; The Johns Hopkins Hospital, Baltimore, United States of America. February 2022. European Heart Journal – Cardiovascular Imaging, Volume 23, Issue Supplement_1 [online]. Available from: https://academic.oup.com/ehjcimaging/article/23/Supplement_1/jeab289.244/6522478
2 Sudden Cardiac Arrest Foundation. January 29, 2020. Latest statistics: 1,000 people suffer sudden cardiac arrest each day in U.S.; only 10% survive [online]. Available from: https://www.sca-aware.org/sca-news/latest-statistics-1000-people-suffer-sudden-cardiac-arrest-each-day-in-us-only-10-survive [Accessed May 1, 2023]
3 J Comp Eff Res. October 2021. Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/34225473/ [Accessed May 1, 2023]
We believe that AI-enabled solutions can help shorten the diagnostic odyssey and improve the lives and outcomes of patients with cardiovascular disease.
